Investigators examined the relationship among enthesitis, synovitis, and peritenon extensor tendon inflammation in patients with psoriatic arthritis.
Investigators evaluated whether subclinical atherosclerosis, as evaluated by carotid ultrasound, is a risk factor for incident cardiovascular events in patients with psoriatic disease.
Researchers examined the efficacy of anti-tumor necrosis factor-a and novel biologic agents to treat dactylitis and enthesitis and compared the results with ACR20 and HAQ scores.
OMERACT endorsed the 66/68 swollen and tender joint count SJC66/TJC68 for inclusion in the Core Outcome Measurement Set for patients with psoriatic arthritis.
Janssen announced positive top-line results from two phase 3 trials of Tremfya (guselkumab) in patients with moderate to severe psoriatic arthritis.
Etanercept monotherapy and combination therapy with etanercept and methotrexate showed greater efficacy than methotrexate monotherapy in patients with psoriatic arthritis.
Investigators assessed cardiovascular risk factors and major adverse cardiovascular events in patients with active psoriatic arthritis who received tofacitinib 5 or 10 mg twice daily plus conventional synthetic disease-modifying antirheumatic drugs.
Researchers used ultrasonography to examine whether the duration of psoriatic dactylitis was related to different patterns of extracapsular and synovial-based inflammation.
Researchers evaluated the efficacy and safety of apremilast in patients with psoriatic arthritis.
The etanercept biosimilar SB4 is a cost-effective alternative therapy that can be considered for the treatment of patients with plaque psoriasis and psoriatic arthritis.